Validation of the new Swedish vaccination register - Accuracy and completeness of register data.

Immunisation Information Systems National Immunisation Programs (four more possible) Vaccination Registers Vaccination coverage

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
22 05 2020
Historique:
received: 21 01 2020
revised: 06 04 2020
accepted: 07 04 2020
pubmed: 4 5 2020
medline: 16 3 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

The aims of this study are to validate infant vaccination data in the Swedish Vaccination Register (SVR) to the Swedish administrative coverage reports, and to assess differences in register-based vaccination coverage estimates between providers using different data reporting methods. The study population included all infants born in Sweden with a Swedish Personal Identity Number during 2014 and 2015 (n = 230,220). Data on all National Immunisation Programme vaccinations administered before 24 months of age were collected from the SVR and from administrative coverage reports. Information regarding data registration methods in the SVR were collected from national and regional authorities. Coverage from health care providers using single registration methods, where vaccination data were transferred automatically from the electronic health care record to the SVR, was compared to that from providers using double registration methods where data had to be added into the SVR in a separate process. For 98,4% of the study population at least one vaccination was recorded in the SVR. The coverage of 3-dose DTP-containing (87,1%) and 1 dose MMR (91,1%) in the register did not reach administrative data coverage (97,4% for 3-dose DTP-containing and 97,0% for MMR). Single registration procedures yielded significantly higher coverage than double registration procedures (92,24% vs 87,10%, p < 0,0001). A regional switch from double to single registration increased coverage from 80,0 to 95,2%. The SVR is a valuable data source for vaccination coverage monitoring. For research purposes, the SVR provides valuable data, since every health care provider is obliged to register all vaccine doses given within the national immunisation program. The SVR shows a high completeness validated by comparison to a very well-functioning administrative data system. Single-registration procedures give more complete data and should be supported by health systems while creating health care registers.

Identifiants

pubmed: 32359874
pii: S0264-410X(20)30490-4
doi: 10.1016/j.vaccine.2020.04.020
pii:
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4104-4110

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Cecilia Chrapkowska (C)

Public Health Agency of Sweden, Nobels väg 18, 171 82 Solna, Sweden; Karolinska Institutet, Department of Women's and Children's Health, Solna, Sweden. Electronic address: cecilia.chrapkowska@ki.se.

Ilias Galanis (I)

Public Health Agency of Sweden, Nobels väg 18, 171 82 Solna, Sweden.

Malin Kark (M)

Public Health Agency of Sweden, Nobels väg 18, 171 82 Solna, Sweden; Karolinska Institutet, Department of Women's and Children's Health, Solna, Sweden.

Tiia Lepp (T)

Public Health Agency of Sweden, Nobels väg 18, 171 82 Solna, Sweden.

Ann Lindstrand (A)

Public Health Agency of Sweden, Nobels väg 18, 171 82 Solna, Sweden.

Adam Roth (A)

Public Health Agency of Sweden, Nobels väg 18, 171 82 Solna, Sweden; Department of Translational Medicine, Lund University, Malmö, Sweden.

Anna Nilsson (A)

Karolinska Institutet, Department of Women's and Children's Health, Solna, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH